Veracyte VCYT
- Market cap
- $3.9B
- PE
- 35.0×
- 2y median 66.2×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 7.0×
- EV/EBIT
- 27.9×
- Revenue, 12 months
- $561.9M
- +17% on a year ago
- Net margin
- 20.4%
- Free cash flow yield
- 4.2%
Veracyte trades at 35.0× trailing earnings, cheaper than 86% of the last ten years. Revenue was $561.9M over the last twelve months, up 17% on a year earlier with a 20% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $90.1M+19% | $98.2M+22% | $96.8M+18% | $114.4M+27% | $115.9M+29% | $118.6M+21% | $114.5M+18% | $130.2M+14% | $131.9M+14% | $140.6M+19% | $139.1M+22% | $150.3M+16% | |
| Cost of revenue | $27.6M+6% | $29.4M+10% | $31.5M+20% | $33.6M+13% | $33.9M+23% | $37.1M+26% | $32.4M+3% | $37.7M+12% | $37.9M+12% | $36M−3% | $35.2M+9% | $39M+4% |
| Gross profit | $57.7M+16% | $68.8M+29% | $62.5M+11% | $77.9M+40% | $79M+37% | $78.8M+14% | $79.5M+27% | $89.8M+15% | $91.3M+16% | $102M+30% | $101.2M+27% | $108.5M+21% |
| R&D | $13.3M+24% | $18.7M+65% | $16M+25% | $16.5M+31% | $17.6M+32% | $19.3M+3% | $17.7M+11% | $16.3M−1% | $16M−9% | $20.8M+8% | $27.1M+53% | $29.4M+81% |
| SG&A | $40.7M−6% | $49.1M+16% | $50M+6% | $56M+10% | $48.4M+19% | $51.7M+6% | $58.3M+17% | $57.6M+3% | $51.7M+7% | $43.3M−16% | $50.8M−13% | $55.7M−3% |
| −$31.7M+228% | −$35.5M+555% | −$4.7M−56% | $4.6M | $12M | $4.2M | $2.9M | −$5.3M | $22.9M+91% | $37.2M+791% | $22.6M+680% | $23M | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | −$29.8M+236% | −$30.5M+786% | −$1.9M−76% | $7.4M | $16.8M | $3.4M | $7.4M | $1.3M−83% | $18.9M+12% | $40.6M+1080% | $30M+304% | $26.5M+2022% |
| −$154K+1% | −$2.2M | −$44K | $1.6M+1202% | $1.7M | −$1.7M−23% | $381K | $2.2M+37% | −$248K | −$515K−69% | $1.3M+233% | $1M−54% | |
| Net income | −$29.6M+240% | −$28.3M+636% | −$1.9M−77% | $5.7M | $15.2M | $5.1M | $7M | −$980K | $19.1M+26% | $41.1M+705% | $28.7M+307% | $25.5M |
| −$0.41+242% | −$0.39+680% | −$0.02−82% | $0.07 | $0.19 | $0.06 | $0.09 | −$0.01 | $0.24+26% | $0.50+733% | $0.35+289% | $0.31 | |
| 72.8M+2% | 73.1M+2% | 74.8M+4% | 77.2M+7% | 78.5M+8% | 80.6M+10% | 80.1M+7% | 78.4M+2% | 79.7M+2% | 82.4M+2% | 81.3M+2% | 82.1M+5% |
Gross profit: 44 periods, Q3 FY12 to Q4 FY23: not printed by the filing, worked out from its own lines.
Interest expense: Q1 FY13: 6 months less the 3 months printed beside them.
Net income: 31 periods, Q3 FY12 to Q1 FY20: not printed by the filing, worked out from its own lines.
EPS, diluted: 6 periods, Q4 FY12 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 4 periods, Q4 FY12 to Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY24 and Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Diagnostics & Research nearest Veracyte's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| VCYTVeracyte | $3.9B | 35.0× | 66.2× | n/m | 7.0× | +17% | 20.4% |
| CDNACareDx | $4.5B | 35.9× | 19.2× | n/m | 9.1× | +39% | 25.9% |
| BLLNBillionToOne | $5.2B | 170× | 152× | n/m | 13.1× | +90% | 9.5% |
| LNTHLantheus | $6.5B | 24.3× | 24.0× | n/m | 4.2× | +2% | 17.7% |
| CAICaris Life Sciences | $9.1B | 86.8× | 78.4× | n/m | 9.2× | +85% | 10.6% |
| BIOBio-Rad Laboratories | $9.8B | 44.4× | 30.9× | n/m | 3.8× | +1% | 8.6% |
| RVTYRevvity | $16.9B | 72.2× | 35.1× | n/m | 5.8× | +4% | 8.2% |
| MEDPMedpace | $18.1B | 38.0× | 34.5× | n/m | 6.5× | +25% | 17.7% |
| DGXQuest Diagnostics | $27.5B | 24.9× | 19.3× | n/m | 2.3× | +9% | 9.5% |
| LHLabcorp | $28.9B | 29.4× | 19.5× | 18.8× | 2.0× | +6% | 7.0% |
| NRCNRC Health | $536.6M | 97.0× | 35.2× | n/m | 3.8× | −0% | 4.2% |
| Peer median | $9.4B | 41.2× | 32.7× | 18.8× | 5.0× | +8% | 9.5% |
Investors who own it
Investors we follow who held Veracyte at the end of Jun 30, 2026, from their 13F filings.
- Cathie WoodARK Investment Management0.9% of portfoliotrimmed
- Ron BaronBaron Capital0.1% of portfoliotrimmed
More on Veracyte
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #4of 39Diagnostics and research stocks with the highest profit margins
- #7of 28Diagnostics and research stocks with the highest free cash flow yield
- #6of 20Diagnostics and research stocks with the lowest PE ratio
- #9of 25Diagnostics and research stocks with the lowest EV/EBIT
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .